THYROID Volume 23, Number 4, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/thy.2012.0614
LETTERS TO THE EDITOR
Intratumor BRAFV600E Heterogeneity and Kinase Inhibitors in the Treatment of Thyroid Cancer: A Call for Participation Mario Vitale
Dear Editor: In general, differentiated thyroid cancer (DTC) patients have an excellent prognosis, and even in the presence of metastatic and radioiodine-resistant disease, the life expectancy of most DTC patients is not reduced. Nevertheless, in *3% of DTC patients, the disease can become (rapidly) progressive, refractory to radioiodine treatment and fatal (1). The therapeutic management of this small group of patients remains a challenge for the clinician whose tools are limited to cytotoxic agents and kinase inhibitors (KIs). Although unusual complete responses to cytotoxic chemotherapy have been described, this treatment is associated with significant toxicity and varying efficacy (2–4). Clinical trials on KIs have shown promise for patients with metastatic radioiodine-resistant (MRR)–DTC and now represent a new treatment strategy for these refractory patients. Small molecules with tyrosine kinase inhibitory capacity have been developed with two main goals: the inhibition of neoangiogenesis and the inhibition of the mitogen-activated protein kinase pathway, which is abnormally activated by mutated kinases. Angiogenesis plays a critical role in tumorcell growth and metastasis, supplying nutrients and oxygen, and facilitating distant metastasis. Therefore, its inhibition is a strategy for the treatment of cancer (5). Vascular endothelial growth factor (VEGF) is overexpressed in thyroid tumors, and the inhibition of its receptor (VEGF-R) signaling has been shown to inhibit the growth of aggressive thyroid cancer in xenograft models, thereby providing a strong rationale for targeting VEGF-Rs in this disease (6,7). More recently, the regulation of the VEGF-R2 protein expression by ubiquitination and its effect on angiogenesis and cell migration observed in papillary thyroid cancer (PTC)–derived cells also suggested a direct effect of VEGF-R inhibitors on PTC cells (8). Advanced cancer results from the progressive increase in favorable genetic alterations. Once established, the survival of cancer cells is tied to the continued expression of the activated genes (oncogenes) or the inactivation of tumor suppressor genes (anti-oncogenes). Accordingly, targeting even a single genetic mutation may affect tumor-cell viability. Activating mutations of BRAF and, less frequently, RAS, as well as RET/ PTC and PTEN rearrangements, are the most frequent genetic
alterations occurring in MRR-DTC. The serine/threonin kinase BRAFV600E, the most frequently altered kinase in DTC, appears as the most promising target for KI-based therapy (9). Preclinical studies suggest that tumors with the BRAFV600E mutation are dependent on BRAFV600E for proliferation and survival this indicates the protein (10–12). To date, the inhibition of VEGF-Rs and BRAFV600E is providing at least a partial rationale for the efficacy of KIs in the treatment of MRR-DTC. Vandetanib, sunitinib, and pazopanib are KIs that affect VEGF-Rs and other kinases, while sorafenib also inhibits BRAFV600E. Clinical trials with these KIs have shown encouraging results in a relevant fraction of patients, although the effect is of a short duration and shows frequent relapses. The encouraging results obtained with sorafenib in many BRAFV600E-positive tumors, including melanomas and thyroid cancers, are consistent with the hypothesis that BRAF inhibition is a promising strategy in MRR-DTC that has become tied to BRAF mutations. The recent progress in the successful application of KIs represents an exciting new option for the treatment of MRR-DTC, but it is important not to lose sight of the dangers that could stem from the underestimation of the limits of this treatment. In recent years, the role of other known oncogenes (i.e., RET/ PTC and mutated RAS) in thyroid carcinogenesis has been reconsidered, leading to the conclusion that more crucial genetic events in PTC are still to be discovered (13–16). More recently, it has been demonstrated, by means of a quantitative assay, that conventional PTCs often consist of a mixture of tumor cells expressing wild-type and mutant BRAF (17,18). The subclonal or even oligoclonal occurrence of BRAFV600E supports the concept that the BRAF mutation may not be the initiating event in thyroid tumorigenesis and this may have important therapeutic implications. Before this direct demonstration, a possible mixed composition of PTCs with respect to the BRAF mutation was suggested by the observation that in some cases, patients with BRAFV600E primary tumors also had or developed BRAFwild-type metastases, and BRAFV600E metastases co-existed or developed in patients with BRAFwild-type primary tumors (19,20). More recently, the study of Sancisi et al. documented the genetic discordance between primary tumors and metastases in two of five metastatic PTCs analyzed, suggesting that this is not a sporadic occurrence (21).
Departments of Medicine and Surgery, University of Salerno, Salerno, Italy.
517
518 Jovanovic et al. performed a microsatellite allelic imbalance and BRAFV600E mutation analysis of synchronous tumor foci from multifocal PTC patients (22). They found that BRAFV600E was not always present in all tumor foci with concordant allelic imbalance changes, indicating that BRAFV600E can occur as a subclonal evolution in PTC. Regardless of whether the heterogeneity of BRAFV600E is the consequence of a secondary event or the effect of the DNA repair mechanisms as hypothesized (23), the subclonality of BRAFV600E in MRR-DTC has important therapeutic implications. A therapeutic strategy based upon BRAF inhibitors in tumors bearing subclonal BRAFV600E could be initially successful in targeting tumor cells expressing the oncogene. After the initial tumor growth arrest and/or shrinkage, oncogene-negative cells that are insensitive or less sensitive to the treatment could restart the growth of the tumor, causing the progression of the disease and escape from the clinical response during treatment. Another consequence of the subclonal presence of BRAFV600E is the occurrence of response at some metastatic sites and a progression in others as a result of different populations of tumor clones with individual drug sensitivity. Therefore, a therapeutic strategy based upon BRAF inhibitors might be inadequate for tumors that contain mutated BRAF in only a subpopulation, and clinical trials should consider this aspect for patient stratification. The BRAF mutation status of the tumor is a parameter that is considered in the majority of the clinical trials of new oral KIs in advanced DTC, particularly for sorafenib and other more selective KIs, to elucidate better the relationship between BRAF activity and outcome with KI treatment. In these trials, the BRAF mutation status was assessed by Sanger sequencing or real-time polymerase chain reaction. The possibility of a mixed-tumor cell population was not taken into consideration, and its therapeutic significance remains unclear. Moreover, concurrent BRAF and RAS mutations, in the same tumor but not necessarily in the same cell, was found in a few cases (17). In light of the heterogeneous composition of PTC, the association between BRAF mutation status and the response to KI treatment must be re-evaluated, taking into account the clonal/subclonal status of BRAFV600E. A stratification of patients based on the percentage of BRAFV600E-bearing cells in the tumor could reveal a significant association with outcomes, enabling the selection of patients who are most likely to respond and reducing the rate of nonresponding patients. With this aim, a new clinical trial has been registered at clinicaltrials.gov (NCT01700699). The study is designed to assess the percentage of BRAFV600E alleles by a quantitative assay in primary tumor tissues, synchronous metastases, and metachronous metastases in MRR-DTC patients treated with a TKI. The study could reveal an association between tumor response to TKIs and a defined BRAFwild-type/ BRAFV600E ratio in the primary tumor and metastasis. The study is currently recruiting participants. Author Disclosure Statement
2.
3. 4.
5. 6.
7.
8.
9. 10.
11.
12.
13.
14.
There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported. References 1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger
15.
M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214. Crouzeix G, Michels JJ, Sevin E, Aide N, Vaur D, Bardet S 2012 Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab 97:3046–3050. Sherman SI 2010 Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 22:464–468. Marotta V, Ramundo V, Camera L, Prete MD, Fonti R, Esposito R, Palmieri G, Salvatore M, Vitale M, Colao A, Faggiano A 2012 Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf) 2012 Sep 25 [Epub ahead of print]; DOI: 10.1111/cen.12057. Ferrara N 2002 VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803. Tuttle RM, Fleisher M, Francis GL, Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87:1737–1742. Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL 2002 Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12:953–961. Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, Harris L, Wan L, Fukushima H, Husain A, Nose V, Fadda G, Sadow PM, Goessling W, North T, Lawler J, Wei W 2012 SCF(beta-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med 209:1289–1307. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245–262. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A, Mascarelli F 2003 Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 278:42409–42418. Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA 2006 Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 12:1785–1793. Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S 2011 Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16:296–309. Unger K, Zitzelsberger H, Salvatore G, Santoro M, Bogdanova T, Braselmann H, Kastner P, Zurnadzhy L, Tronko N, Hutzler P, Thomas G 2004 Heterogeneity in the distribution of RET/PTC rearrangements within individual postChernobyl papillary thyroid carcinomas. J Clin Endocrinol Metab 89:4272–4279. Sapio MR, Guerra A, Marotta V, Campanile E, Formisano R, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G, Vitale M 2011 High growth rate of benign thyroid nodules bearing RET/PTC rearrangements. J Clin Endocrinol Metab 96:E916–919. Guerra A, Sapio MR, Marotta V, Campanile E, Moretti MI, Deandrea M, Motta M, Limone PP, Fenzi G, Rossi G, Vitale M 2011 Prevalence of RET/PTC rearrangement in benign
519
16. 17.
18.
19.
20.
and malignant thyroid nodules and its clinical application. Endocr J 58:31–38. Vitale M 2012 Rethinking the role of oncogenes in papillary thyroid cancer initiation. Front Endocrinol (Lausanne) 3:83. Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G, Vitale M 2012 The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97:517–524. Guerra A, Fugazzola L, Marotta V, Cirillo M, Rossi S, Cirello V, Forno I, Moccia T, Budillon A, Vitale M 2012 A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 97:2333–2340. Vasko V, Hu S, Wu G, Xing JC, Larin A, Savchenko V, Trink B, Xing M 2005 High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90:5265–5269. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, Garcia-Rostan G 2008 BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 68:618–634.
21. Sancisi V, Nicoli D, Ragazzi M, Piana S, Ciarrocchi A 2012 BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 97:E1745–1749. 22. Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK 2008 Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol 215:145–154. 23. Xing M 2012 BRAFV600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab 97:2295– 2298.
Address correspondence to: Mario Vitale, MD Department of Medicine and Surgery University of Salerno Via S. Allende Salerno Italy 84081 E-mail:
[email protected]
